Compare Heron Therapeutics Inc (HRTX) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares MSCI India ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while iShares MSCI India ETF trades at $45.94 (market cap $5.73B). The key difference: iShares MSCI India ETF is far larger — about 84.3× Heron Therapeutics Inc's market cap, and iShares MSCI India ETF is more actively traded (6,797,522 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares MSCI India ETF for 57 Days on average.
| HRTX | INDA | |
|---|---|---|
Market Cap | $68.01M | $5.73B |
Volume | 1,891,941 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $55.29 |
52-Week Low | $0.27 | $45.42 |
Typical Hold Time | 35 Days | 57 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
INDA is trading at $46.12, down 1.31% with a bearish technical signal across moving averages and oscillators. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Technical indicators show oversold conditions with RSI readings below 30, while support and resistance cluster around $46.
The outlook remains cautious given India's infrastructure constraints and global trade tensions. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy security concerns, weather-related agricultural impacts, and IT sector weakness. Current technical oversold conditions may present entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
